|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 11 (June 1), 1999:
pp. 3662-3671
Factors Associated With Outcome After Cord Blood Transplantation in
Children With Acute Leukemia
Franco Locatelli,
Vanderson Rocha,
Claude Chastang,
William Arcese,
Gerard Michel,
Manoel Abecasis,
Chiara Messina,
Juan Ortega,
Isabel Badell-Serra,
Emanuel Plouvier,
Gerard Souillet,
Jean-Pierre Jouet,
Ricardo Pasquini,
Euripedes Ferreira,
Federico Garnier, and
Eliane Gluckman on behalf of Eurocord-Cord Blood Transplant Group
From the Clinica Pediatrica, IRCCS Policlinico San Matteo, University
of Pavia, Italy; Hôpital Saint-Louis, Paris, France; University
La Sapienza, Rome, Italy; Hôpital La Timone, Marseille, France;
Instituto Portugues de Oncologia, Lisboa, Portugal; Clinica
Oncoematologica Pediatrica e Centro delle Leucemie Infantili, Padova,
Italy; Hospital Infantil Vall d'Hebron, Barcelona, Spain; Hospital
Santa Creu i Sant Pau, Barcelona, Spain; Hôpital Saint Jacques,
Besançon, Hôpital Debrousse, Lyon, and Hôpital Claude
Huriez, Lille, France; Hospital de Clinicas, Curitiba, and Hospital
Albert Einstein, Sao Paulo, Brazil.
We have analyzed factors influencing the outcome of 102 children
with acute leukemia given a cord blood transplantation (CBT) and
reported to the Eurocord Registry. Seventy patients with acute lymphoblastic and 32 with acute myeloid leukemia were given either a
related (n = 42) or an unrelated (n = 60) CBT. Children given CBT during first or second complete remission were considered as
belonging to the good-risk group (n = 66), whereas those who received a transplant in a more advanced stage of disease were assigned
to the poor-risk group (n = 36). In the related group (RCBT), 12 of
42 patients received transplantation from an HLA-disparate donor,
whereas in the unrelated group (UCBT) 54 of 60 received an HLA
mismatched CBT. Kaplan-Meier estimates for neutrophil recovery at day
60 were 84% ± 7% in RCBT and 79 ± 6% in UCBT
(P = .16). In multivariate analysis, the most important
factor influencing neutrophil engraftment in UCBT was a nucleated cell
dose infused greater than 3.7 × 107/kg
(P = .05, relative risk [RR] of 1.85, 95% confidence
interval [CI]: 0.98-3.4). The incidence of grade II through IV acute
graft-versus-host disease was 41% ± 8% in the RCBT group and 37% ± 6% in the UCBT group (P = .59). Kaplan-Meier estimates
of 2-year event-free survival (EFS) after RCBT or UCBT were 39% ± 8% and 30% ± 7%, respectively (P = .19). In
multivariate analysis, the most important factor influencing EFS was
disease status at time of transplantation: good-risk patients had a
2-year EFS of 49% ± 7% as compared to 8% ± 5% in patients with
more advanced disease (P = .0003, RR: 0.40, 95% CI: 0.24 to 0.65). This was a consequence of both an increased 1-year transplant
related mortality and a higher 2-year relapse rate in the poor-risk
group (65% ± 9% and 77% ± 14%, respectively), as compared
with good risk patients (34% ± 6% and 31% ± 9%,
respectively). These data confirm that allogeneic CBT from either a
related or an unrelated donor is a feasible procedure able to cure a
significant proportion of children with acute leukemia, especially if
transplanted in a favorable phase of disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. R. Verneris, C. G. Brunstein, J. Barker, M. L. MacMillan, T. DeFor, D. H. McKenna, M. J. Burke, B. R. Blazar, J. S. Miller, P. B. McGlave, et al.
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
Blood,
November 5, 2009;
114(19):
4293 - 4299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Moscardo, J. Sanz, L. Senent, S. Cantero, J. de la Rubia, P. Montesinos, D. Planelles, I. Lorenzo, J. Cervera, J. Palau, et al.
Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies
Haematologica,
June 1, 2009;
94(6):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. MacMillan, D. J. Weisdorf, C. G. Brunstein, Q. Cao, T. E. DeFor, M. R. Verneris, B. R. Blazar, and J. E. Wagner
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
Blood,
March 12, 2009;
113(11):
2410 - 2415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R Placzek, I-M. Chung, H. M Macedo, S. Ismail, T. Mortera Blanco, M. Lim, J. Min Cha, I. Fauzi, Y. Kang, D. C.L Yeo, et al.
Stem cell bioprocessing: fundamentals and principles
J R Soc Interface,
March 6, 2009;
6(32):
209 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lisini, M. Zecca, G. Giorgiani, D. Montagna, R. Cristantielli, M. Labirio, P. Grignani, C. Previdere, A. Di Cesare-Merlone, G. Amendola, et al.
Donor/recipient mixed chimerism does not predict graft failure in children with {beta}-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling
Haematologica,
December 1, 2008;
93(12):
1859 - 1867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Iori, W. Arcese, F. Milano, E. Calabrese, G. F. Torelli, W. Barberi, M. G. Mascolo, L. De Felice, M. Screnci, B. Lucarelli, et al.
Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up
Haematologica,
August 1, 2007;
92(8):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Ballen
New trends in umbilical cord blood transplantation
Blood,
May 15, 2005;
105(10):
3786 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Takahashi, T. Iseki, J. Ooi, A. Tomonari, K. Takasugi, Y. Shimohakamada, T. Yamada, K. Uchimaru, A. Tojo, N. Shirafuji, et al.
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies
Blood,
December 1, 2004;
104(12):
3813 - 3820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Laughlin, M. Eapen, P. Rubinstein, J. E. Wagner, M.-J. Zhang, R. E. Champlin, C. Stevens, J. N. Barker, R. P. Gale, H. M. Lazarus, et al.
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia
N. Engl. J. Med.,
November 25, 2004;
351(22):
2265 - 2275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montagna, F. Locatelli, A. Moretta, D. Lisini, C. Previdere, P. Grignani, P. DeStefano, G. Giorgiani, E. Montini, S. Pagani, et al.
T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation
Blood,
June 1, 2004;
103(11):
4322 - 4329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Michel, V. Rocha, S. Chevret, W. Arcese, K.-W. Chan, A. Filipovich, T. A. Takahashi, M. Vowels, J. Ortega, P. Bordigoni, et al.
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis
Blood,
December 15, 2003;
102(13):
4290 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Frassoni, M. Podesta, R. Maccario, G. Giorgiani, G. Rossi, M. Zecca, A. Bacigalupo, G. Piaggio, and F. Locatelli
Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation
Blood,
August 1, 2003;
102(3):
1138 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Jaroscak, K. Goltry, A. Smith, B. Waters-Pick, P. L. Martin, T. A. Driscoll, R. Howrey, N. Chao, J. Douville, S. Burhop, et al.
Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System
Blood,
June 15, 2003;
101(12):
5061 - 5067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Grewal, J. N. Barker, S. M. Davies, and J. E. Wagner
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Blood,
June 1, 2003;
101(11):
4233 - 4244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, V. Rocha, W. Reed, F. Bernaudin, M. Ertem, S. Grafakos, B. Brichard, X. Li, A. Nagler, G. Giorgiani, et al.
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease
Blood,
March 15, 2003;
101(6):
2137 - 2143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Wagner, J. N. Barker, T. E. DeFor, K. S. Baker, B. R. Blazar, C. Eide, A. Goldman, J. Kersey, W. Krivit, M. L. MacMillan, et al.
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
Blood,
August 13, 2002;
100(5):
1611 - 1618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Ballen, P. S. Becker, R. V. B. Emmons, T. J. Fitzgerald, C. C. Hsieh, Q. Liu, C. Heyes, Y. Clark, W. Levy, J. F. Lambert, et al.
Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy
Blood,
June 28, 2002;
100(2):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Muscaritoli, G. Grieco, S. Capria, A. Paola Iori, and F. Rossi Fanelli
Nutritional and metabolic support in patients undergoing bone marrow transplantation
Am. J. Clinical Nutrition,
February 1, 2002;
75(2):
183 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Sanz, S. Saavedra, D. Planelles, L. Senent, J. Cervera, E. Barragan, C. Jimenez, L. Larrea, G. Martin, J. Martinez, et al.
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies
Blood,
October 15, 2001;
98(8):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Laughlin, J. Barker, B. Bambach, O. N. Koc, D. A. Rizzieri, J. E. Wagner, S. L. Gerson, H. M. Lazarus, M. Cairo, C. E. Stevens, et al.
Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors
N. Engl. J. Med.,
June 14, 2001;
344(24):
1815 - 1822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Barker, S. M. Davies, T. DeFor, N. K. C. Ramsay, D. J. Weisdorf, and J. E. Wagner
Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis
Blood,
May 15, 2001;
97(10):
2957 - 2961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Rocha, J. Cornish, E. L. Sievers, A. Filipovich, F. Locatelli, C. Peters, M. Remberger, G. Michel, W. Arcese, S. Dallorso, et al.
Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia
Blood,
May 15, 2001;
97(10):
2962 - 2971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Rosler, J. E. Brandt, J. Chute, and R. Hoffman
An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells
Blood,
November 15, 2000;
96(10):
3414 - 3421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Migliaccio, J. W. Adamson, C. E. Stevens, N. L. Dobrila, C. M. Carrier, and P. Rubinstein
Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity
Blood,
October 15, 2000;
96(8):
2717 - 2722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Rocha, J. E. Wagner, K. A. Sobocinski, J. P. Klein, M.-J. Zhang, M. M. Horowitz, E. Gluckman, and The Eurocord and International Bone Marrow Transpl
Graft-Versus-Host Disease in Children Who Have Received a Cord-Blood or Bone Marrow Transplant from an HLA-Identical Sibling
N. Engl. J. Med.,
June 22, 2000;
342(25):
1846 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Matthews, M. Wadhwa, C. Bird, F. E. Borras, and C. V. Navarrete
Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells
J. Immunol.,
June 15, 2000;
164(12):
6206 - 6212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
